Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 130Lymphoma, Large B-Cell, Diffuse 101Lymphoma, Follicular 90Leukemia, Lymphocytic, Chronic, B-Cell 82Lymphoma 63Lymphoma, B-Cell 43Recurrence 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 23Neoplasms 22Leukemia 10Hematologic Diseases 10Lymphatic Diseases 8Multiple Myeloma 7Immunoproliferative Disorders 6Hematologic Neoplasms 6Waldenstrom Macroglobulinemia 5Lymphoproliferative Disorders 5Leukemia, B-Cell 5Arthritis, Rheumatoid 5Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Immune System Diseases 3Dendritic Cell Sarcoma, Interdigitating 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Off-Label Use × Rituximab × Clear all
NCT02654379 2018-04-09

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Hoffmann-La Roche

Completed
1,408 enrolled

Off-Label Use

Data powered by HemOnc (CC BY 4.0) Colophon âš¡